Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Albuvirtide on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Frontier Biotechnologies Inc. (前沿生物药业(南京)股份有限公司)
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Albuvirtide is a long-acting HIV medicine given by a weekly drip into a vein. It was discovered and developed in China by Frontier Biotechnologies of Nanjing, and is sold there under the brand name 艾可宁® (Aikening). The company describes it as the first long-acting HIV-1 fusion inhibitor to be approved anywhere.
China's drug regulator (then the CFDA, now the NMPA) approved it in 2018 for:
It sits within our infections and specialty medicines range and should be prescribed and supervised by an HIV specialist or infectious disease physician.
HIV has to fuse its outer coat with a CD4 immune cell before it can get inside. A viral protein called gp41 drives that fusion. This medicine is a short chain of 34 amino acids carrying a small chemical add-on that latches on to albumin, the most common protein in blood. Once bound, the peptide blocks gp41 and stops the virus at the very first step of infection. The albumin link keeps it in the body far longer than an ordinary peptide, which is why one dose a week is enough.
The phase 3 TALENT study, run at 12 hospitals in China, enrolled adults whose first-line HIV treatment had stopped working (viral load above 1,000 copies/mL after more than six months). One group took the new weekly infusion plus a boosted protease inhibitor; the other took a standard comparison regimen. In the interim analysis published in the Chinese Medical Journal (2020), 80.4% of people on the infusion-based regimen had an undetectable viral load (below 50 copies/mL) at week 48, against 66.0% in the comparison group. Among people who followed the protocol fully, the figures were 94.9% and 74.4%. The new regimen met the non-inferiority goal.
The TALENT trial used this schedule:
Each vial contains 160 mg, so one 320 mg dose uses two vials. The infusion is given in a clinic or hospital. Your HIV specialist will confirm the exact dose and the medicines it is combined with.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Overall safety: in the TALENT interim safety analysis (93 people on the new regimen, 99 on the comparison regimen), severe (grade 3–4) side effects were reported at similar rates: 14.0% and 11.1% respectively.
Staying on schedule: missing weekly doses can let the virus grow back and become resistant to treatment. The trial authors stress close follow-up for this reason. The study enrolled adults only; discuss pregnancy, breastfeeding or use in children with your specialist before starting.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
This injection can be brought in only for a named patient, by the patient or a government hospital, under the rules for importing unapproved medicines into India. Please keep ready:
After our team has checked the prescription and medical reports, and an import permit is in place where one is required.
No. It is approved in China only. CDSCO has not approved it, Indian pharmacies do not stock it, and it has no US FDA approval.
A doctor can still request it for one specific patient through the Named Patient Program route, which allows legal, prescription-based import of a medicine that is not registered in India.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The Chinese pack states that the vials must be kept sealed, away from light, in a refrigerator at 2°C to 8°C, so every shipment moves under cold-chain shipping to the treating clinic. Since a weekly dose uses two vials, we plan supply in blocks of several weeks so treatment is not interrupted. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
People living with HIV across India can access this medicine through a regulated import route, with refrigerated delivery to the clinic that gives the weekly infusion, on a valid specialist's prescription.
Large infectious disease departments in the capital can receive weekly supplies quickly from our New Delhi dispatch point.
The refrigerated vials go directly to the clinic where the weekly infusion is given.
An HIV specialist in Bangalore can send the prescription and viral load reports to start a named-patient request.
Clinics in Chennai can plan several weeks of stock in one shipment to match the dosing calendar.
Deliveries are timed so the clinic has vials ready before each scheduled infusion day.
Cold-chain packaging keeps the vials between 2°C and 8°C on the journey to eastern India.
Patients and doctors in Pune receive a written quote and timeline before any order is placed.
The treating physician shares the treatment history, and we handle the import paperwork from there.
Supplies can be sent to the hospital pharmacy that gives the weekly drip.
Covers patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating centre.
We arrange refrigerated delivery to hospitals across Uttar Pradesh that manage HIV care.
Patients in Kerala can have the vials delivered to their clinic in Kochi or a nearby city.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 18 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message